BR0108816A - Quinoline derivatives as alpha-2 antagonists - Google Patents
Quinoline derivatives as alpha-2 antagonistsInfo
- Publication number
- BR0108816A BR0108816A BR0108816-5A BR0108816A BR0108816A BR 0108816 A BR0108816 A BR 0108816A BR 0108816 A BR0108816 A BR 0108816A BR 0108816 A BR0108816 A BR 0108816A
- Authority
- BR
- Brazil
- Prior art keywords
- alpha
- antagonists
- quinoline derivatives
- antagonist
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
"DERIVADOS DE QUINOLINA COMO ANTAGONISTAS ALFA-2". A invenção provê um composto da fórmula (I), onde A, Ra, Rb, R1 a R5, m e t são como definido como revelado, ou um seu éster ou sal farmaceuticamente aceitável, útil como antagonista alfa-2. Os compostos I podem ser utilizados para o tratamento de doenças ou condições onde os antagonistas alfa-2 são indicados como eficazes"QUINOLINE DERIVATIVES AS ALPHA-2 ANTAGONISTS". The invention provides a compound of formula (I), where A, Ra, Rb, R1 to R5, m and t are as defined as disclosed, or a pharmaceutically acceptable ester or salt thereof, useful as an alpha-2 antagonist. Compounds I can be used to treat diseases or conditions where alpha-2 antagonists are indicated to be effective
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20000480A FI20000480A0 (en) | 2000-03-01 | 2000-03-01 | Quinoline and naphthalene derivatives as alpha-2 antagonists |
PCT/FI2001/000203 WO2001064645A2 (en) | 2000-03-01 | 2001-02-28 | Derivatives of quinoline as alpha-2 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0108816A true BR0108816A (en) | 2002-12-10 |
Family
ID=8557801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0108816-5A BR0108816A (en) | 2000-03-01 | 2001-02-28 | Quinoline derivatives as alpha-2 antagonists |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1263733A2 (en) |
JP (1) | JP2003525274A (en) |
KR (1) | KR20020089372A (en) |
CN (1) | CN1468224A (en) |
AR (1) | AR034249A1 (en) |
AU (1) | AU2001239331A1 (en) |
BR (1) | BR0108816A (en) |
CA (1) | CA2400657A1 (en) |
CZ (1) | CZ20022880A3 (en) |
EE (1) | EE200200490A (en) |
FI (1) | FI20000480A0 (en) |
HU (1) | HUP0204458A3 (en) |
IL (1) | IL151093A0 (en) |
MX (1) | MXPA02008402A (en) |
NO (1) | NO20024159L (en) |
PE (1) | PE20011084A1 (en) |
PL (1) | PL357874A1 (en) |
RU (1) | RU2002125944A (en) |
SK (1) | SK12332002A3 (en) |
WO (1) | WO2001064645A2 (en) |
ZA (1) | ZA200206956B (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1474401A2 (en) * | 2002-02-05 | 2004-11-10 | Novo Nordisk A/S | Novel aryl- and heteroarylpiperazines |
NZ535950A (en) | 2002-04-03 | 2007-11-30 | Orion Corp | Polycyclic compounds as potent alpha2-adrenoceptor antagonists |
US20050203100A1 (en) * | 2002-04-03 | 2005-09-15 | Jukka Sallinen | Use of an alfa2-adrenoreceptor antagonist for cns-related diseases |
US7009053B2 (en) * | 2002-04-30 | 2006-03-07 | Yungjin Pharmaceuticals Co., Ltd. | Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same |
WO2004067513A1 (en) * | 2003-01-27 | 2004-08-12 | Oy Juvantia Pharma Ltd | Antagonists for alpha-2 adrenoceptors |
ES2375929T3 (en) | 2005-07-04 | 2012-03-07 | High Point Pharmaceuticals, Llc | HISTAMINE RECEIVER ANTAGONISTS H3. |
EP1948629A1 (en) | 2005-10-31 | 2008-07-30 | Janssen Pharmaceutica N.V. | Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor |
WO2007078335A2 (en) * | 2005-12-21 | 2007-07-12 | Decode Genetics, Ehf. | Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation |
EP2029553A1 (en) * | 2006-05-22 | 2009-03-04 | Janssen Pharmaceutica, N.V. | Substituted pyrazinone derivatives for use as a medicine |
CA2653062A1 (en) | 2006-05-23 | 2007-11-29 | Transtech Pharma, Inc. | 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament |
PT2079732E (en) | 2006-05-29 | 2012-02-02 | High Point Pharmaceuticals Llc | 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist |
EP2014656A3 (en) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
TWI457122B (en) | 2007-07-20 | 2014-10-21 | Orion Corp | 2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases |
EP2356106A1 (en) | 2008-10-07 | 2011-08-17 | Schering Corporation | Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators |
TW201024282A (en) | 2008-11-20 | 2010-07-01 | Orion Corp | New pharmaceutical compounds |
JP2013513588A (en) * | 2009-12-11 | 2013-04-22 | ジーンコード エーエス | Method for facilitating survival of neural cells using mimic or RET signaling pathway activators of GDNF family ligand (GFL) |
CN103524413B (en) * | 2012-07-04 | 2016-04-20 | 江苏先声药物研究有限公司 | hydrogenated acridine derivative and application thereof |
JOP20200052A1 (en) * | 2013-12-19 | 2017-06-16 | Bayer Pharma AG | Substituted piperidinyl-tetrahydroquinolines and their use as alpha-2c adrenoreceptor antagonists |
JP6483804B2 (en) * | 2014-03-31 | 2019-03-13 | ミレクス ファーマシューティカルズ, エルエルシーMirx Pharmaceuticals, Llc | Novel HDMX inhibitors and their use for cancer treatment |
WO2016135138A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135139A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135137A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135140A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer |
CN107337641B (en) * | 2017-07-01 | 2020-04-28 | 广东医科大学 | 4-flexible amino-2-arylvinyl quinoline derivative and preparation method and application thereof |
CA3230249A1 (en) * | 2021-09-07 | 2023-03-16 | Paul Gregor | Compounds and pharmaceutical compositions comprising inhibitors of amyloid peptide interactions with glycosaminoglycans, methods of treatment, and use thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
-
2000
- 2000-03-01 FI FI20000480A patent/FI20000480A0/en unknown
-
2001
- 2001-02-28 PL PL01357874A patent/PL357874A1/en not_active Application Discontinuation
- 2001-02-28 EP EP01913918A patent/EP1263733A2/en not_active Withdrawn
- 2001-02-28 CA CA002400657A patent/CA2400657A1/en not_active Abandoned
- 2001-02-28 CN CNA018059236A patent/CN1468224A/en active Pending
- 2001-02-28 EE EEP200200490A patent/EE200200490A/en unknown
- 2001-02-28 CZ CZ20022880A patent/CZ20022880A3/en unknown
- 2001-02-28 KR KR1020027011453A patent/KR20020089372A/en not_active Application Discontinuation
- 2001-02-28 MX MXPA02008402A patent/MXPA02008402A/en unknown
- 2001-02-28 JP JP2001563488A patent/JP2003525274A/en active Pending
- 2001-02-28 HU HU0204458A patent/HUP0204458A3/en unknown
- 2001-02-28 SK SK1233-2002A patent/SK12332002A3/en unknown
- 2001-02-28 AU AU2001239331A patent/AU2001239331A1/en not_active Abandoned
- 2001-02-28 WO PCT/FI2001/000203 patent/WO2001064645A2/en not_active Application Discontinuation
- 2001-02-28 BR BR0108816-5A patent/BR0108816A/en not_active Application Discontinuation
- 2001-02-28 RU RU2002125944/04A patent/RU2002125944A/en not_active Application Discontinuation
- 2001-02-28 IL IL15109301A patent/IL151093A0/en unknown
- 2001-03-01 PE PE2001000208A patent/PE20011084A1/en not_active Application Discontinuation
- 2001-03-01 AR ARP010100993A patent/AR034249A1/en unknown
-
2002
- 2002-08-29 ZA ZA200206956A patent/ZA200206956B/en unknown
- 2002-08-30 NO NO20024159A patent/NO20024159L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PE20011084A1 (en) | 2001-10-25 |
CZ20022880A3 (en) | 2003-06-18 |
EP1263733A2 (en) | 2002-12-11 |
CA2400657A1 (en) | 2001-09-07 |
EE200200490A (en) | 2003-12-15 |
IL151093A0 (en) | 2003-04-10 |
MXPA02008402A (en) | 2003-10-14 |
NO20024159D0 (en) | 2002-08-30 |
CN1468224A (en) | 2004-01-14 |
NO20024159L (en) | 2002-08-30 |
RU2002125944A (en) | 2004-02-27 |
FI20000480A0 (en) | 2000-03-01 |
SK12332002A3 (en) | 2003-07-01 |
HUP0204458A3 (en) | 2004-07-28 |
WO2001064645A2 (en) | 2001-09-07 |
PL357874A1 (en) | 2004-07-26 |
AU2001239331A1 (en) | 2001-09-12 |
HUP0204458A2 (en) | 2003-04-28 |
JP2003525274A (en) | 2003-08-26 |
AR034249A1 (en) | 2004-02-18 |
ZA200206956B (en) | 2003-12-01 |
WO2001064645A3 (en) | 2001-12-27 |
KR20020089372A (en) | 2002-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0108816A (en) | Quinoline derivatives as alpha-2 antagonists | |
TR200200579T2 (en) | Amino-thyrazolpyridine derivatives. | |
EA200300354A1 (en) | Quinoline derivatives as tyrosine kinase inhibitors | |
TR200201505T2 (en) | Pirazolopyrimidines as therapeutic agents | |
CO4990963A1 (en) | SRC FAMILY DOMAIN SH2 INHIBITORS | |
BG66085B1 (en) | Phenylalanine derivatives | |
PT1104760E (en) | SULFAMOYL-HETEROARILPIRAZOLE COMPOUNDS AS ANALGESIC AND ANTI-INFLAMMATORY AGENTS | |
NO20044731L (en) | Quinoline and Isoquinoline Derivatives Process for Preparation thereof and its Use as Inflammatory Inhibitors | |
ATE253545T1 (en) | BIARYLACETIC ACID DERIVATIVES AND THEIR USE AS COX-2 INHIBITORS | |
BR0109703A (en) | Piperazine Derivatives | |
DE60010076D1 (en) | CHINOLINE DERIVATIVES AS AN ANTIBACTERIAL AGENTS | |
BR0313743A (en) | Benzimidazole quinolinones and uses of these | |
DK1539700T3 (en) | 8-hydroxy quinoline derivatives | |
EA200300248A1 (en) | BICYCLOPIRASOLES, ACTIVE AS KINASE INHIBITORS, METHOD OF THEIR RECEIVING AND INCLUDING THEIR PHARMACEUTICAL COMPOSITIONS | |
PT1104759E (en) | HETEROARIL-PHENYL-PYRAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | |
ATE316962T1 (en) | PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 | |
BR0315662A (en) | 1- (4-Benzyl-piperazin-1-yl) -3-phenyl-propenone derivatives | |
DK1458393T3 (en) | Substituted diketopiperazines as oxytocin antagonists | |
BR0309028A (en) | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | |
EA200200742A1 (en) | 1,2-DIARYLBENZYMIDAZOLEY FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE ACTIVATION OF MICROGLY | |
TR200103457T2 (en) | 4-Phenyl-Pyrimidine Derivatives. | |
SE9902267D0 (en) | New compounds | |
EE200100520A (en) | N- (2-phenyl-4-aminobutyl) -1-naphthamides as neurokinin-1 receptor antagonists | |
ATE253359T1 (en) | ANTITHRBOTIC AGENTS | |
DK1204658T3 (en) | Benzofurylpiperazine-serotonin agonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |